Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for RLYB.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2020. Start Trial.
Date Value
June 30, 2026 45.92M
March 31, 2026 -7.978M
December 31, 2025 -4.679M
September 30, 2025 -6.55M
June 30, 2025 -8.379M
March 31, 2025 -10.20M
December 31, 2024 -9.862M
September 30, 2024 -13.54M
June 30, 2024 -10.42M
March 31, 2024 -15.46M
December 31, 2023 -11.64M
September 30, 2023 -16.47M
June 30, 2023 -13.38M
Date Value
March 31, 2023 -18.76M
December 31, 2022 -15.26M
September 30, 2022 -14.74M
June 30, 2022 -13.55M
March 31, 2022 -13.73M
December 31, 2021 -9.886M
September 30, 2021 -10.87M
June 30, 2021 -12.85M
March 31, 2021 -11.93M
December 31, 2020 -7.261M
September 30, 2020 -5.623M
June 30, 2020 -3.616M
March 31, 2020 -5.539M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Q32 Bio, Inc. -3.075M
Beam Therapeutics, Inc. -66.10M
C4 Therapeutics, Inc. -1.574M
Cullinan Therapeutics, Inc. -38.22M
Arrowhead Pharmaceuticals, Inc. -177.47M